ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,220.31
-0.02%
Dow Jones
39,399.09
-0.08%
US Dollar vs MXN
16.8424
0.26%
Brent Oil
82.235
-1.17%
Bitcoin
61,359.49
-2.45%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU
  6. Crossject (ALCJ)

  7. Crossject (ALCJ) Noticias

ALCJ

Crossject (ALCJ)

Crossject
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:EU:ALCJ
FechaHoraFuenteTítuloSímboloCompañía
02/05/202410:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
02/05/202410:30GlobeNewswire Inc.Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en EuropeEU:ALCJCrossject
30/04/202412:05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
25/04/202400:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
25/04/202400:32GlobeNewswire Inc.Crossject communique ses résultats financiers audités pour 2023EU:ALCJCrossject
10/04/202409:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
02/04/202411:35GlobeNewswire Inc.Crossject trading on Euronext to resume as usual on Wednesday April 3EU:ALCJCrossject
02/04/202411:35GlobeNewswire Inc.La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avrilEU:ALCJCrossject
02/04/202403:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
02/04/202403:30GlobeNewswire Inc.Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023EU:ALCJCrossject
08/03/202400:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
08/03/202400:30GlobeNewswire Inc.Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024EU:ALCJCrossject
27/02/202401:30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
27/02/202401:30GlobeNewswire Inc.Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranchesEU:ALCJCrossject
06/02/202410:30GlobeNewswire Inc.Crossject publie une mise à jour stratégique de ses priorités pour 2024EU:ALCJCrossject
06/02/202410:30GlobeNewswire Inc.Crossject provides strategic update on priorities for 2024EU:ALCJCrossject
01/02/202411:15GlobeNewswire Inc.Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CETEU:ALCJCrossject
01/02/202411:15GlobeNewswire Inc.Crossject organisera un webcast le 6 février à 17h30 pour faire le point sur sa stratégie commercialeEU:ALCJCrossject
09/01/202409:21GlobeNewswire Inc.Crossject to present at Biotech Showcase on January 9 at 16:30 PTEU:ALCJCrossject
09/01/202409:21GlobeNewswire Inc.Crossject annonce l’initiation de la couverture de son titre par ODDO BHFEU:ALCJCrossject
04/01/202411:00GlobeNewswire Inc.Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-UnisEU:ALCJCrossject
04/01/202411:00GlobeNewswire Inc.Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®EU:ALCJCrossject
22/12/202300:30GlobeNewswire Inc.Crossject signs ZEPIZURE® commercialization agreement for northern EuropeEU:ALCJCrossject
22/12/202300:30GlobeNewswire Inc.Crossject signe un accord de commercialisation pour ZEPIZURE® en Europe du NordEU:ALCJCrossject
28/11/202300:30GlobeNewswire Inc.Crossject announces initiation of coverage by ODDO BHFEU:ALCJCrossject
26/09/202310:35GlobeNewswire Inc.Crossject reports financial results and business highlights for first half of 2023EU:ALCJCrossject
11/09/202300:30GlobeNewswire Inc.Crossject announces significant improvement in Gaïa ESG ratingEU:ALCJCrossject
11/09/202300:30GlobeNewswire Inc.Crossject annonce une nouvelle nette amélioration de sa notation ESG GaïaEU:ALCJCrossject
05/09/202306:00GlobeNewswire Inc.Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizuresEU:ALCJCrossject
05/09/202300:30GlobeNewswire Inc.Crossject annonce avoir passé avec succès des audits européens et américain pour la fabrication de ZENEO® Midazolam dans le traitement des crises d’épilepsieEU:ALCJCrossject
 Showing the most relevant articles for your search:EU:ALCJ

Su Consulta Reciente

AMEX
XLE
Energy Select Sector SPDR
CCOM
SILVER
SILVER
PM
XAUUSD
Gold vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
FX
USDMXN
US Dollar vs MXN
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
CCOM
US500
US 500
SPI
SP500
S&P 500
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
NYSE
VZ
Verizon Communications
FX
EURMXN
Euro vs MXN
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados